In a little more than six weeks, from March 19 to May 1, the Mechanical Ventilator Milano (MVM) has gone from conception to reality, as it is now shifting to production and to support of patients affected severely by COVID-19. As of May 1, 2020, the United States Food and Drug Administration (U.S. FDA) declared that the MVM falls within the scope of the Emergency Use Authorization (EUA) for ventilators.
The MVM is an innovative ventilator, conceived and designed by an international collaboration of particle physicists and developed in cooperation with other relevant scientific communities. Its mechanical design is simple, using a small number of parts to facilitate rapid production. The powerful and sophisticated control unit, programmed by a large number of researchers, results in strong and safe performance for the care and recovery of COVID-19 patients. Achieving this result in such a short time was made possible thanks to the cooperation of laboratories, institutes, universities and companies mainly across Italy, Canada and the United States, maximizing the benefits that come from the sharing of skills and resources.